Recursion Pharmaceuticals, Inc. (RXRX)

Market Cap	1.90B -7.2%
Revenue (ttm)	74.68M +26.9%
Net Income	-644.76M
EPS	-1.44
Shares Out	528.20M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	16,375,626
Open	3.850
Previous Close	3.750
Day's Range	3.530 - 3.900
52-Week Range	2.800 - 7.180
Beta	1.01
Analysts	Buy
Price Target	7.50 (+108.33%)
Earnings Date	May 4, 2026

About RXRX

Recursion Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in the decoding biology and chemistry by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery in the United States and the United Kingdom. The company develops REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-617, which is in Phase 1/2 clinical trial to treat advanced solid tumors; REC-1245, which is in Phase 1/2 clinical trial to treat ...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Apr 16, 2021
• Employees: 600
• Stock Exchange: NASDAQ
• Ticker Symbol: RXRX
• Website: https://www.recursion.com

Financial Performance

In 2025, Recursion Pharmaceuticals's revenue was $74.68 million, an increase of 26.92% compared to the previous year's $58.84 million. Losses were -$644.76 million, 39.1% more than in 2024.

Analyst Summary

According to 4 analysts, the average rating for RXRX stock is "Buy." The 12-month stock price target is $7.5, which is an increase of 108.33% from the latest price.

Price Target

$7.5

(108.33% upside)

Analyst Consensus: Buy